Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence

  • End date
    Apr 7, 2025
  • participants needed
  • sponsor
    Gustave Roussy, Cancer Campus, Grand Paris
Updated on 15 October 2021


To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints

Condition Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)
Treatment MRI
Clinical Study IdentifierNCT05071001
SponsorGustave Roussy, Cancer Campus, Grand Paris
Last Modified on15 October 2021


Yes No Not Sure

Inclusion Criteria

For study OSE A and B
Patients treated for a bone sarcoma: Ewing or osteosarcoma
Age under 19 years at initial diagnosis
Treated in the Pediatric Oncology Department of Gustave
For patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in
complete remission at least 5 years after diagnosis
Treated with at least one course of HDMTX for osteosarcoma
Treated without HDMTX for Ewing sarcoma
Time interval between the end of treatment and inclusion >10 y
Age > 21 y at inclusion
Patients with informed consent signed
Patient under guardianship
Affiliated to French health insurance or beneficiary of the same or equivalent
For study OSE- B only
Treated with at least 8 courses of HDMTX for osteosarcoma
Treated without HDMTX for Ewing sarcoma
Patients with Ewing sarcoma will have to be matched with osteosarcoma patients according to age at the time of treatment, sex, and duration of follow-up
School level equivalent of at least the end of primary school

Exclusion Criteria

For study OSE A and B
Brain radiotherapy
Previous relapse except those treated by local treatment without any chemotherapy
Second malignancy treated with chemotherapy
High dose chemotherapy with stem cell support
Non-French speaking patients
Pregnant and breastfeeding women
For study OSE- B only
Patient deprived of his liberty by a judicial or administrative decision
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note